Every 8-K that Cellectar Biosciences INC NEW (CLRB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CLRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLRB filings page.
Cellectar Biosciences reported second quarter 2026 results and provided an update on its oncology pipeline. For the quarter ended June 30, 2026, the company recorded a net loss of $6,930,653, compared with $5,447,911 a year earlier. Operating expenses were $7,196,012, including $4,557,383 in research and development and $2,638,629 in general and administrative costs.
On the balance sheet, Cellectar reported cash and cash equivalents of $33,993,982 and total assets of $36,639,086 as of June 30, 2026, with stockholders’ equity of $29,871,833. The company initiated site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström macroglobulinemia, with a New Drug Application submission planned for mid‑2027 under the FDA’s accelerated approval program. It also presented Phase 2b CLOVER WaM data, began enrolling and dosing patients in a Phase 1b trial of CLR 125 in triple‑negative breast cancer, and reported publication of Phase 1 data in the journal Cancers.
Cellectar Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on July 7, 2026. Stockholders elected Class III directors Andrew Gu and Douglas J. Swirsky to new three-year terms. They approved an amendment to the 2021 Stock Incentive Plan to increase shares reserved for issuance by 2,000,000 shares of common stock. Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 and, on a non-binding advisory basis, approved executive officer compensation. In addition, stockholders approved the exercise of warrants to purchase up to 39,618,078 shares of common stock under Nasdaq rules, making a planned adjournment proposal moot.
Cellectar Biosciences announced upcoming board changes and a new consulting role for an exiting director. Stefan D. Loren, Ph.D. informed the board he will not stand for reelection as a Class III director at the 2026 annual meeting, and his current term will end at that time. The company states his decision is not due to any disagreement over operations, policies, or practices.
Cellectar entered into a one-year consulting agreement with Dr. Loren, effective July 8, 2026, under which he will receive $15,000 per quarter and a stock option grant for 15,000 shares at the end of the term, with all his granted options remaining exercisable for 10 years from their grant dates. Separately, under a previously disclosed board designation side letter linked to a May 4, 2026 securities purchase agreement, Nantahala Capital Management selected Andrew Gu as its board designee. The board appointed Gu on May 18, 2026 as a Class III director and member of the Audit Committee. The company notes he has no disclosable related-party transactions or family relationships with its directors or officers.
Cellectar Biosciences, Inc. reported a first quarter 2026 net loss of $5.65 million, improving from a loss of $6.60 million a year earlier, with basic and diluted net loss per share of $1.33 on 4,240,129 weighted-average shares. Operating expenses were $5.79 million, mainly for research and development and general and administrative costs. The company ended March 31, 2026 with $8.35 million in cash and cash equivalents and total assets of $11.12 million.
Cellectar highlighted positive 12‑month follow-on data for iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia, including an overall response rate of 83.6%, median progression-free survival of 13.5 months, and a disease control rate of 98.2%. It also completed a financing of up to $140 million to support a confirmatory study and a planned FDA accelerated approval filing, and dosed first patients in a Phase 1b trial of CLR 125 in triple negative breast cancer.
Cellectar Biosciences entered financing deals combining a registered direct offering of 1,618,053 common shares and a concurrent private placement of 2,116,887 shares, 9,471,086 pre-funded warrants and three milestone warrant tranches of 13,206,026 each at exercise prices largely around $2.65–$2.88.
The gross proceeds are expected to be about $35 million before fees, with an 8% cash fee and additional warrant compensation to the placement agent. After issuing these shares, Cellectar will have 7,975,069 common shares outstanding, excluding any shares from warrant exercises.
The company plans to use net proceeds mainly for working capital and to support initiation of a Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia. In Phase 2b WM data, iopofosine showed an 83.6% overall response rate, 61.8% major response rate, 17.8‑month median duration of response and 13.5‑month median progression‑free survival with mostly low‑grade, manageable toxicities.
Cellectar Biosciences reported a narrower net loss for the year ended December 31, 2025 while advancing its radiotherapeutic pipeline. Net loss was $21,791,037 compared with $44,581,446 in 2024, as total operating expenses declined to $22,979,844 from $51,777,698.
Cash and cash equivalents were $13,196,033 at December 31, 2025, down from $23,288,607 a year earlier. Common shares outstanding rose to 4,240,129 from 1,535,996, and total stockholders’ equity decreased to $8,537,164 from $14,294,681. The company plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the European Medicines Agency in Q3 2026 for potential 2027 EU commercialization in Waldenström Macroglobulinemia, and is running a Phase 1b dose‑finding study of CLR 125 in triple negative breast cancer with early data expected by mid‑2026.
Cellectar Biosciences (CLRB) furnished an 8-K announcing it issued a press release with third‑quarter 2025 financial results and a corporate update. The press release covers the quarter ended September 30, 2025 and is provided as Exhibit 99.1 dated November 13, 2025. The company’s common stock trades on The Nasdaq Capital Market under the symbol CLRB.
Cellectar Biosciences entered into warrant exercise inducement letters with certain holders who agreed to exercise existing warrants covering 1,048,094 common shares at an exercise price of $5.25 per share and to pay $0.125 per new warrant. In return, the company issued new Series I and Series II inducement warrants. The transactions closed on October 8, 2025 and generated aggregate gross proceeds of approximately $5.8 million.
The Series I inducement warrants are immediately exercisable at $6.00 per share and expire on October 8, 2030, while the Series II inducement warrants are immediately exercisable at $6.00 per share and expire on April 8, 2027. Cellectar announced an estimated cash and cash equivalents balance of approximately $12.6 million as of September 30, 2025 and anticipates that this, together with approximately $5.2 million in net proceeds from the warrant transactions, will be sufficient to fund operations into the third quarter of 2026.
Cellectar Biosciences, Inc. disclosed a Form 8-K reporting the release of a corporate press statement and related communications. The filing identifies certain securities‑law communication categories including written communications under Rule 425 and soliciting/pre‑commencement communications under Rules 14a‑12, 14d‑2(b), and 13e‑4(c). The company also flagged its status as an emerging growth company and furnished the press release as Exhibit 99.1, with the cover page interactive data included as Exhibit 104. The document is signed by the company’s Chief Financial Officer, indicating formal disclosure and corporate authorization.
Cellectar Biosciences, Inc. filed a current report to note that it issued a press release on August 14, 2025 announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 and is incorporated by reference. The company’s common stock, par value $0.00001 per share, trades on The Nasdaq Capital Market under the symbol CLRB.
Cellectar Biosciences (Nasdaq:CLRB) filed an 8-K to update investors on pipeline progress in connection with a proposed securities offering.
- CLR 125 (Auger I-125): favorable pre-clinical safety, strong uptake in triple-negative breast cancer; Phase 1b dose-finding study planned for 2H 2025.
- CLR 225 (Ac-225 α-emitter): tumor reduction in pancreatic, colorectal and breast models; Phase 1 imaging/dose-escalation study also slated for 2H 2025.
- Both trials depend on new financing.
- Iopofosine CLOVER-WaM Phase 2b in refractory Waldenström macroglobulinemia met its primary endpoint, posting a 58.2% major response rate (vs 20% FDA hurdle) and 83.6% ORR; responses durable with median DOR not reached at 11.4 mo.
Offering proceeds are expected to fund operating expenses and the CLR 125 trial; amount and timing were not disclosed.
Cellectar Biosciences (Nasdaq: CLRB) filed an 8-K disclosing a one-for-thirty reverse stock split of its common stock, effective June 24 2025, through an amendment to its Second Amended and Restated Certificate of Incorporation.
No fractional shares will be issued; instead, all fractional interests will be aggregated, sold by the transfer agent at prevailing market prices, and net cash proceeds distributed pro-rata to affected holders. The action is reported under Item 3.03 (Material Modification to Rights of Security Holders) and Item 5.03 (Charter Amendment). Exhibit 3.1 contains the full amendment and Exhibit 104 provides the Inline XBRL cover page.
The filing, signed by CFO Chad J. Kolean on June 25 2025, materially alters the capital structure and share count for existing investors.
Cellectar Biosciences, Inc. (Nasdaq: CLRB) has filed a Form 8-K to disclose that its stockholders approved, and the board of directors has subsequently set, a one-for-thirty reverse stock split of the company’s common stock. The split will take effect at 12:01 a.m. ET on June 24, 2025 (the “Effective Time”).
At the Effective Time, every 30 shares of issued and outstanding common stock will be automatically combined into 1 share; fractional shares will be paid out in cash. The filing notes that the reverse split will proportionately adjust (i) the share reserves under all company equity-incentive plans, (ii) the share quantities and exercise or conversion prices of outstanding stock options and warrants, and (iii) the conversion ratios of any outstanding preferred stock, thereby keeping the aggregate economic value of each instrument unchanged.
The company attached a press release (Exhibit 99.1) titled “Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split” and an Inline XBRL cover page file (Exhibit 104). No other operational or financial data were provided in this filing.